Table 2.

Differences in activation between 15 participants at clinical high risk for psychosis (CHR) receiving placebo, 19 healthy controls and 15 CHR participants receiving cannabidiol (CBD).

Region	Talairach coordinates			Cluster size, no. of voxels	p Valuea
	x	y	z
Differences between healthy controls and CHR-placebo
Placebo > controls
Parahippocampal gyrus	−18	−33	−13	5	0.002
Parahippocampal gyrus	−25	−44	−7	35	<0.001
Parahippocampal gyrus	18	−33	−3	22	<0.001
Lingual gyrus	−22	−56	3	5	0.003
Controls > placebo
Putamen	−22	11	0	5	0.002
Caudate head	−11	19	0	10	<0.001
Putamen	25	11	3	7	0.001
Putamen	22	15	0	13	<0.001
Differences between CHR-placebo and CHR-CBD
Placebo > CBD
Amygdala	−25	−4	−16	4	0.002
Parahippocampal gyrus	−18	−56	−7	11	<0.001
CBD > placebo
Putamen	25	15	0	6	0.001
Putamen	−18	11	7	16	<0.001

^aCorrected for <1 false-positive cluster.